|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007226,
umls-concept:C0017245,
umls-concept:C0023820,
umls-concept:C0080103,
umls-concept:C0087111,
umls-concept:C0441471,
umls-concept:C0814861,
umls-concept:C1257890,
umls-concept:C1549054,
umls-concept:C1979963,
umls-concept:C2003903
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-12-14
|
|
pubmed:abstractText |
The significant cardiovascular disease (CVD) event reduction in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) could not be fully explained by the 6% increase in high-density lipoprotein (HDL) cholesterol with the fibrate gemfibrozil. We examined whether measurement of HDL subpopulations provided additional information relative to CVD risk reduction. The HDL subpopulations were characterized by 2-dimensional gel electrophoresis in subjects who were treated with gemfibrozil (n = 754) or placebo (n = 741). In this study, samples obtained at the 3-month visit were used; and data were analyzed prospectively using CVD events (coronary heart disease death, myocardial infarction, or stroke) during the 5.1 years of follow-up. Analyses in the gemfibrozil arm showed that subjects with recurrent CVD events had significantly higher prebeta-1 and had significantly lower alpha-1 and alpha-2 HDL levels than those without such events. Prebeta-1 level was a significant positive predictor; alpha-1 and alpha-2 levels were significant negative risk factors for future CVD events. alpha-2 level was superior to HDL cholesterol level in CVD-risk assessment after adjustment for established risk factors. Gemfibrozil treatment was associated with 3% to 6% decreases in the small, lipid-poor prebeta-1 HDL and in the large, lipid-rich alpha-1 and alpha-2 HDL and with increases in the small alpha-3 (3%) and prealpha-3 (16%) HDLs. Although the use of gemfibrozil has been associated with reduction in CVD events in VA-HIT, HDL subpopulation analysis indicates that gemfibrozil-mediated improvement in CVD risk might not be the result of its effects on HDL. It is quite possible that much of the cardiovascular benefits of gemfibrozil are due to a much wider spectrum of effects on metabolic processes that is not reflected by changes in blood lipids and HDL subpopulations.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-10634817,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-11116070,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-11268266,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-12204809,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-12364554,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-12637338,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-12665498,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-1402396,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-1445850,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-15071125,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-15388521,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-16061948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-16123324,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-16310551,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-16397146,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-16534013,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-16832162,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-16832168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-3126809,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-7548123,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-7718018,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-8172849,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-8420235,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-8640404,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-8831920,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-8969638,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18078862-9678787
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0026-0495
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
77-83
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18078862-Cardiovascular Diseases,
pubmed-meshheading:18078862-Coronary Disease,
pubmed-meshheading:18078862-Gemfibrozil,
pubmed-meshheading:18078862-Humans,
pubmed-meshheading:18078862-Hypertension,
pubmed-meshheading:18078862-Hypolipidemic Agents,
pubmed-meshheading:18078862-Lipids,
pubmed-meshheading:18078862-Lipoproteins, HDL,
pubmed-meshheading:18078862-Male,
pubmed-meshheading:18078862-Placebos,
pubmed-meshheading:18078862-Proportional Hazards Models,
pubmed-meshheading:18078862-Prospective Studies,
pubmed-meshheading:18078862-Risk Reduction Behavior,
pubmed-meshheading:18078862-United States,
pubmed-meshheading:18078862-United States Department of Veterans Affairs
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
|
|
pubmed:affiliation |
Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA. bela.asztalos@tufts.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Controlled Clinical Trial,
Multicenter Study,
Research Support, N.I.H., Extramural
|
